Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lapatinib Clear all
Terminated Phase 1 Interventional

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

NCT00251433
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, docetaxel, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 1, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

NCT01769508
View directory record Official record
Conditions
HER2 Positive Esophagogastric Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00769470
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel, lapatinib ditosylate
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

NCT01783756
View directory record Official record
Conditions
Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
lapatinib ditosylate, everolimus, capecitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

NCT00347919
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
19
States / cities
Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

NCT00316875
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, Doxil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 1, 2026, 5:06 PM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

NCT00073528
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Lapatinib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
84
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

NCT00430781
View directory record Official record
Conditions
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Interventions
pazopanib (GW786034), lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

NCT00680901
View directory record Official record
Conditions
Neoplasms, Gastrointestinal Tract
Interventions
Lapatinib, Placebo, Capecitabine, Oxaliplatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
10
States / cities
Alhambra, California • Fullerton, California • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

NCT00095940
View directory record Official record
Conditions
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligodendroglioma
Interventions
lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, positron emission tomography, magnetic resonance imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

NCT00089999
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

NCT00741260
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Capecitabine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 1, 2026, 5:06 PM EDT
Withdrawn Phase 2 Interventional

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

NCT00343759
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 1, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856
View directory record Official record
Conditions
Relapsed Breast Cancer, Neoplasms, Breast
Interventions
Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

NCT00389922
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lapatinib ditosylate, Vinorelbine ditartrate, comparative genomic hybridization, cytogenetic analysis, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01591577
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma Multiforme
Interventions
Lapatinib/Temozolomide/radiation
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00114283
View directory record Official record
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Rollover Study Of Lapatinib In Cancer Patients

NCT00169533
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
GW572016 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
10
States / cities
Indianapolis, Indiana • Detroit, Michigan • Lebanon, New Hampshire + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 1, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

NCT01499160
View directory record Official record
Conditions
Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
Interventions
letrozole, lapatinib, everolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 1, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688
View directory record Official record
Conditions
Brain Cancer, Pediatric Cancers
Interventions
Bevacizumab, Lapatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 1, 2026, 5:06 PM EDT